Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
BofA downgraded Hims & Hers (HIMS) to Underperform from Buy with a price target of $18, down from $32. Amazon (AMZN) launched a cash-pay ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
Hims & Hers Health, Inc.’s HIMS investors are reaping some gains from the stock of late. Shares of the San Francisco, ...
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.